Conduit Pharmaceuticals Inc. has filed a Prospectus Supplement No. 1 to update and supplement information contained in its previous prospectus dated May 2, 2024, with details from its Quarterly Report for the quarter ended March 31, 2024. The supplement, filed with the SEC on May 14, 2024, includes the offer and sale of up to 8,771,470 shares of common stock and 16,033,000 shares underlying warrants by selling securityholders. The shares include those issued in private placements, held by the Sponsor, and issued to A.G.P./Alliance Global Partners, Cizzle Biotechnology Holdings PLC, and Vela Technologies Plc upon exercising options. The shares also include those issuable upon the exercise of warrants issued in connection with a private placement, to A.G.P. upon completion of a Business Combination, to...Show More

Conduit Pharmaceuticals Inc. has filed a Prospectus Supplement No. 1 to update and supplement information contained in its previous prospectus dated May 2, 2024, with details from its Quarterly Report for the quarter ended March 31, 2024. The supplement, filed with the SEC on May 14, 2024, includes the offer and sale of up to 8,771,470 shares of common stock and 16,033,000 shares underlying warrants by selling securityholders. The shares include those issued in private placements, held by the Sponsor, and issued to A.G.P./Alliance Global Partners, Cizzle Biotechnology Holdings PLC, and Vela Technologies Plc upon exercising options. The shares also include those issuable upon the exercise of warrants issued in connection with a private placement, to A.G.P. upon completion of a Business Combination, to the Sponsor, and public warrants from Murphy Canyon Acquisition Corp.'s initial public offering. The company's common stock and public warrants are listed on The Nasdaq under the symbols 'CDT' and 'CDTTW', respectively. As of May 15, 2024, the last quoted sale price for the common stock was $2.97 per share. Conduit Pharmaceuticals, an emerging growth company, has attached the Quarterly Report to the prospectus supplement, advising investors to read both documents carefully before investing.